Additional use of glycated hemoglobin for diagnosis of type 2 diabetes in people undergoing coronary angiography reveals a subgroup at increased cardiovascular risk

Diabetes Care

Volumn 34, Issue 11, 2011, Pages 2471-2473

  Silbernagel, Guenther ^a,b   Kleber, Marcus E ^a,c   Grammer, Tanja B ^d   Winkelmann, Bernhard R ^e   Boehm, Bernhard O ^f   März, Winfried ^c,d,g  

^a Ludwigshafen Risk and Cardiovascular Health Study Nonprofit LLC   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c SYNLAB ACADEMY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Cardiology Group Frankfurt Sachsenhausen   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; DIAGNOSTIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; AGED; CAUSE OF DEATH; GERMANY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK FACTOR;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84857082088     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1046     Document Type: Article

References (15)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62-S67
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
3. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-420
4. Gerstein HC, Swedberg K, Carlsson J, et al.; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008;168:1699-1704
5. Brewer N, Wright CS, Travier N, et al. A New Zealand linkage study examining the associations between A1C concentration and mortality. Diabetes Care 2008;31:1144-1149
6. Levitan EB, Liu S, Stampfer MJ, et al. HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia 2008;51:267-275
7. Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010;7:e1000278
8. McNeely MJ, McClelland RL, Bild DE, et al. The association between A1C and subclinical cardiovascular disease: the multiethnic study of atherosclerosis. Diabetes Care 2009;32:1727-1733
9. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
10. Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, März W. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care 2011;34:1355-1361
11. Winkelmann BR, Marz W, Boehm BO, et al.; LURIC Study Group (Ludwigshafen Risk and Cardiovascular Health). Rationale and design of the LURIC studyda resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2(Suppl. 1):S1-S73
12. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
13. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151-157 (Pubitemid 47057520)
14. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-1850 (Pubitemid 41071098)
15. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545-1551 (Pubitemid 47124186)